Japan Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032

Description

Japan biologics market size is projected to exhibit a growth rate (CAGR) of 6.10% during 2024-2032. The growing demand for precision medicine approaches, increasing focus on treating rare diseases, and rising prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, represent some of the key factors driving the market.

Biologics comprise a wide range of pharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. They are derived from living organisms or their components, such as cells, proteins, genes, or tissues. They are produced through biotechnological methods, unlike traditional chemical-based drugs that are synthesized through chemical processes. They interact with specific targets in the body to achieve therapeutic effects. They are known for their high specificity and efficacy, often resulting in fewer side effects compared to conventional drugs. They stimulate the immune system to produce an immune response without causing the disease itself, helping to protect individuals from various viruses and bacteria. They can be tailored to specific genetic or molecular characteristics of disease of patient, enabling personalized treatment approaches. They promote tissue regeneration and wound healing and have fewer side-effects as compared to traditional chemical drugs. They aid in treating certain types of cancer by enhancing the immune response of the body against cancer cells. They assist in addressing rare diseases and orphan diseases that affect a small population. They are used to treat, prevent, or manage various medical conditions and diseases. As they improve the quality of life for patients by effectively managing symptoms and slowing disease progression, the demand for biologics is rising in Japan.

Japan Biologics Market Trends:

At present, the increasing prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, among individuals represents one of the major factors contributing to the market growth in Japan. Moreover, the rising usage of biologics, as they reduce the frequency and severity of hospitalizations, is strengthening the growth of the market in the country. Apart from this, the escalating demand for precision medicine approaches is offering a positive market outlook. Additionally, the increasing awareness among patients about the benefits of biologics, such as fewer side effects, reduced hospital stays, and long-lasting therapeutic effects, is providing lucrative growth opportunities to industry investors in Japan. In line with this, the growing demand for immunotherapies and monoclonal antibodies for treating cancer is influencing the market positively. In addition, innovations in bioproduction methods benefit in cost-effective and efficient production of biologics, which is bolstering the growth of the market. Besides this, the rising number of clinical trials for biologics in the country is propelling the market growth. Furthermore, the increasing focus on treating rare diseases among the masses is impelling the market growth. The technological advancement in biotechnology and genomics enhances the discovery and development of novel biologics, which is also supporting the market growth in Japan.

Japan Biologics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on source, product, disease, and manufacturing.

Source Insights:

Microbial
Mammalian
Others

The report has provided a detailed breakup and analysis of the market based on the source. This includes microbial, mammalian, and others.

Product Insights:

Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense, RNAi and Molecular Therapy
Others

A detailed breakup and analysis of the market based on the product have also been provided in the report. This includes monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi and molecular therapy, and others.

Disease Insights:

Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others

The report has provided a detailed breakup and analysis of the market based on the disease. This includes oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others.

Manufacturing Insights:

Outsourced
In-House

A detailed breakup and analysis of the market based on the manufacturing have also been provided in the report. This includes outsourced and in-house.

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region

The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan biologics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biologics market?
What is the breakup of the Japan biologics market on the basis of source?
What is the breakup of the Japan biologics market on the basis of product?
What is the breakup of the Japan biologics market on the basis of disease?
What is the breakup of the Japan biologics market on the basis of manufacturing?
What are the various stages in the value chain of the Japan biologics market?
What are the key driving factors and challenges in the Japan biologics?
What is the structure of the Japan biologics market and who are the key players?
What is the degree of competition in the Japan biologics market?

Product Code: SR112024A19698

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biologics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biologics Market Landscape

5.1 Historical and Current Market Trends (2018-2023)
5.2 Market Forecast (2024-2032)

6 Japan Biologics Market - Breakup by Source

6.1 Microbial
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2018-2023)
- 6.1.3 Market Forecast (2024-2032)
6.2 Mammalian
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2018-2023)
- 6.2.3 Market Forecast (2024-2032)
6.3 Others
- 6.3.1 Historical and Current Market Trends (2018-2023)
- 6.3.2 Market Forecast (2024-2032)

7 Japan Biologics Market - Breakup by Product

7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2018-2023)
- 7.1.3 Market Forecast (2024-2032)
7.2 Vaccines
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2018-2023)
- 7.2.3 Market Forecast (2024-2032)
7.3 Recombinant Proteins
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2018-2023)
- 7.3.3 Market Forecast (2024-2032)
7.4 Antisense, RNAi and Molecular Therapy
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2018-2023)
- 7.4.3 Market Forecast (2024-2032)
7.5 Others
- 7.5.1 Historical and Current Market Trends (2018-2023)
- 7.5.2 Market Forecast (2024-2032)

8 Japan Biologics Market - Breakup by Disease

8.1 Oncology
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2018-2023)
- 8.1.3 Market Forecast (2024-2032)
8.2 Immunological Disorders
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2018-2023)
- 8.2.3 Market Forecast (2024-2032)
8.3 Cardiovascular Disorders
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2018-2023)
- 8.3.3 Market Forecast (2024-2032)
8.4 Hematological Disorders
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2018-2023)
- 8.4.3 Market Forecast (2024-2032)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2018-2023)
- 8.5.2 Market Forecast (2024-2032)

9 Japan Biologics Market - Breakup by Manufacturing

9.1 Outsourced
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2018-2023)
- 9.1.3 Market Forecast (2024-2032)
9.2 In-House
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2018-2023)
- 9.2.3 Market Forecast (2024-2032)

10 Japan Biologics Market - Breakup by Region

10.1 Kanto Region
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2018-2023)
- 10.1.3 Market Breakup by Source
- 10.1.4 Market Breakup by Product
- 10.1.5 Market Breakup by Disease
- 10.1.6 Market Breakup by Manufacturing
- 10.1.7 Key Players
- 10.1.8 Market Forecast (2024-2032)
10.2 Kansai/Kinki Region
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2018-2023)
- 10.2.3 Market Breakup by Source
- 10.2.4 Market Breakup by Product
- 10.2.5 Market Breakup by Disease
- 10.2.6 Market Breakup by Manufacturing
- 10.2.7 Key Players
- 10.2.8 Market Forecast (2024-2032)
10.3 Central/ Chubu Region
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2018-2023)
- 10.3.3 Market Breakup by Source
- 10.3.4 Market Breakup by Product
- 10.3.5 Market Breakup by Disease
- 10.3.6 Market Breakup by Manufacturing
- 10.3.7 Key Players
- 10.3.8 Market Forecast (2024-2032)
10.4 Kyushu-Okinawa Region
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2018-2023)
- 10.4.3 Market Breakup by Source
- 10.4.4 Market Breakup by Product
- 10.4.5 Market Breakup by Disease
- 10.4.6 Market Breakup by Manufacturing
- 10.4.7 Key Players
- 10.4.8 Market Forecast (2024-2032)
10.5 Tohoku Region
- 10.5.1 Overview
- 10.5.2 Historical and Current Market Trends (2018-2023)
- 10.5.3 Market Breakup by Source
- 10.5.4 Market Breakup by Product
- 10.5.5 Market Breakup by Disease
- 10.5.6 Market Breakup by Manufacturing
- 10.5.7 Key Players
- 10.5.8 Market Forecast (2024-2032)
10.6 Chugoku Region
- 10.6.1 Overview
- 10.6.2 Historical and Current Market Trends (2018-2023)
- 10.6.3 Market Breakup by Source
- 10.6.4 Market Breakup by Product
- 10.6.5 Market Breakup by Disease
- 10.6.6 Market Breakup by Manufacturing
- 10.6.7 Key Players
- 10.6.8 Market Forecast (2024-2032)
10.7 Hokkaido Region
- 10.7.1 Overview
- 10.7.2 Historical and Current Market Trends (2018-2023)
- 10.7.3 Market Breakup by Source
- 10.7.4 Market Breakup by Product
- 10.7.5 Market Breakup by Disease
- 10.7.6 Market Breakup by Manufacturing
- 10.7.7 Key Players
- 10.7.8 Market Forecast (2024-2032)
10.8 Shikoku Region
- 10.8.1 Overview
- 10.8.2 Historical and Current Market Trends (2018-2023)
- 10.8.3 Market Breakup by Source
- 10.8.4 Market Breakup by Product
- 10.8.5 Market Breakup by Disease
- 10.8.6 Market Breakup by Manufacturing
- 10.8.7 Key Players
- 10.8.8 Market Forecast (2024-2032)

11 Japan Biologics Market - Competitive Landscape

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players

12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events

Company names have not been provided here as this is a sample TOC. The complete list is provided in the report.

13 Japan Biologics Market - Industry Analysis

13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
13.3 Value Chain Analysis